A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

计划入组 150 人 · 首次发布于 2025 年 4 月 22 日

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

计划入组 78 人 · 首次发布于 2022 年 3 月 23 日

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

计划入组 353 人 · 首次发布于 2021 年 8 月 10 日

ARO-ALK7

ARO-PNPLA3

ARO-SOD1

Arrowhead Pharmaceuticals

United States

ACO

LKC TECHNOLOGIES, INC.

United States

Arrowhead Pharmaceuticals Achieves FDA Approval for Rodemplo, Reports Strong Financial Turnaround

Arrowhead Pharmaceuticals Advances RNAi Therapies ARO-INHBE and ARO-ALK7 for Obesity Treatment

Arrowhead Pharmaceuticals Launches First-in-Human Trial of ARO-ALK7 for Obesity Treatment